HIV Release and Restriction
HIV 释放和限制
基本信息
- 批准号:9564939
- 负责人:
- 金额:$ 62.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:ATP phosphohydrolaseAntiviral AgentsBindingBiochemicalCarrier ProteinsCellsCellular biologyComplexCrowdingCytoskeletal FilamentsElectronsElementsEventFaceFamily memberFilamentFluorescenceGenesHIVHIV BuddingHIV-1HumanImageIndividualIntegration Host FactorsLettersLipidsMembraneMethodsModelingMusNatureNeckPathway interactionsPeptidesPolymersPrimatesProcessProteinsResolutionRetrotranspositionRodentSaimiriSiteSorting - Cell MovementStructureTestingTotal Internal Reflection FluorescentToxic effectVariantViralVirionVirus ReplicationYeastsbaseblocking factorcofactorconstrictiondesignlight microscopymembrane modelmouse genomenovelprotein transportreconstructionrecruitscaffoldstructural biologytraffickingvirus envelope
项目摘要
ABSTRACT
This Project is designed to elucidate the mechanistic bases for HIV-1 budding and its inhibition by the host
factor retroCHMP3. To initiate budding, HIV-1 Gag binds ESCRT-I1-4 and ALIX5-7, two early-acting factors in the
host Endosomal Sorting Complexes Required for Transport (ESCRT) pathway. These factors, in turn, recruit
the late-acting ESCRT factors CHMP2, CHMP4 (ESCRT-III) and VPS4 (AAA ATPase)2,8-10 (reviewed in refs.
11-16). Numerous models for membrane constriction and fission have been proposed.17-26 We favor those in
which: 1) ESCRT-III proteins form spiraling filaments that recruit VPS4 and constrict the membrane neck from
the cytoplasmic face and 2) The VPS4 ATPase promotes lipid mixing by remodeling the underlying ESCRT-III
scaffold. We now propose to determine the structural bases for membrane remodeling by ESCRT-III filaments
and VPS4 (Aims 1 and 2), characterize how mammalian retroCHMP3 (ESCRT-III) proteins can inhibit HIV
budding without inducing cellular toxicity (Aim 3), and image ESCRT assemblies within budding virions by
electron cryotomography (Aim 4). These studies will reveal how HIV-1 uses the host ESCRT-III/VPS4
machinery to exit cells and how host retroCHMP3 proteins can specifically inhibit this process.
摘要
本项目旨在阐明HIV-1萌发及其被宿主抑制的机制基础
逆转录因子CHMP3。为了启动萌发,HIV-1 Gag与ESCRT-I1-4和ALIX5-7结合,这两个早期作用因子在
运输所需的宿主内体分选复合体(ESCRT)途径。这些因素反过来又招募了
迟效ESCRT因子CHMP2、CHMP4(ESCRT-III)和Vps4(AAA-ATPase)2、8-10(参考文献)。
11-16)。已经提出了许多膜收缩和分裂的模型。17-26我们倾向于那些
其中:1)ESCRT-III蛋白形成螺旋状的细丝,招募Vps4并收缩膜颈部
2)Vps4 ATPase通过重塑潜在的ESCRT-III促进脂质混合
脚手架。我们现在建议确定ESCRT-III细丝重塑膜的结构基础。
和Vps4(目标1和2),描述了哺乳动物反转录CHMP3(ESCRT-III)蛋白如何抑制HIV
萌芽而不诱导细胞毒性(目标3),并通过以下方法成像萌芽病毒粒子内的ESCRT组件
电子冷冻断层摄影术(目标4)。这些研究将揭示HIV-1如何利用宿主ESCRT-III/Vps4
退出细胞的机制,以及宿主反转录CHMP3蛋白如何特异性地抑制这一过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adam Frost其他文献
Adam Frost的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Adam Frost', 18)}}的其他基金
Toward Atomic Resolution of Membranes and Membrane-Associated Machines
膜和膜相关机器的原子分辨率
- 批准号:
9117230 - 财政年份:2013
- 资助金额:
$ 62.81万 - 项目类别:
Toward Atomic Resolution of Membranes and Membrane-Associated Machines
膜和膜相关机器的原子分辨率
- 批准号:
8572065 - 财政年份:2013
- 资助金额:
$ 62.81万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 62.81万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 62.81万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 62.81万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 62.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 62.81万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 62.81万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 62.81万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 62.81万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 62.81万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 62.81万 - 项目类别: